EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more

Arina Martynchyk iD, Eliza A Hawkes iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19456 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Arina Martynchyk und 1 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia. Hauptthemen laut MEDLINE: Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one‐size‐fits‐all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K inhibitors? The report by Soumerai et al. of zandelisib with zanubrutinib in follicular and mantle cell lymphoma is an important addition to the data. Commentary on: Soumerai et al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. Br J Haematol 2024;204:1762‐1770.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoinositide-3 Kinase InhibitorsHumansLymphoma, Mantle-CellLymphomaLymphoma, FollicularPyrazolesPyrimidinesProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsPiperidines

Stichwörter der Autor:innen

Pi3K inhibitorslymphomazandelisib

Substanzen

Phosphoinositide-3 Kinase InhibitorszanubrutinibPyrazolesPyrimidinesProtein Kinase InhibitorsPiperidines

Autor:innen und Institutionen

  • Olivia Newton-John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Arina Martynchyk, Eliza A Hawkes

Zitieren

APA

Martynchyk, A., & Hawkes, E. A. (2024). Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more. British Journal of Haematology. https://doi.org/10.1111/bjh.19456

Vancouver

Martynchyk A, Hawkes EA. Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more. British Journal of Haematology. 2024. doi:10.1111/bjh.19456

BibTeX
@article{Martynchyk2024,
  author = {Martynchyk, Arina and Hawkes, Eliza A},
  title = {Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19456}
}
Kostenlos starten →